Protein Inhibitors - ABT-263 (CAS: 923564-51-6)

ABT-263 (CAS: 923564-51-6)

Catalog #：EBC51003

Biological Activity

Synonyms

Navitoclax, ABT263, ABT 263

Chemical Name

(R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide

Application

ABT-263 is a bcl-2 family protein inhibitor

CAS Number

923564-51-6

Purity

≥99%

Molecular Weight

974.61

Molecular Formula

C₄₇H₅₅ClF₃N₅O₆S₃

SMILES

CC1(C)CCC(=C(CN2CCN(CC2)C2=CC=C(C=C2)C(=O)NS(=O)(=O)C2=CC(=C(N[C@H](CCN3CCOCC3)CSC3=CC=CC=C3)C=C2)S(=O)(=O)C(F)(F)F)C1)C1=CC=C(Cl)C=C1

Target & IC50

EOL1: IC50 = 6.69 nM
NKM-1: IC50 = 16.99 nM
ML-2: IC50 = 19.83 nM
BV-173: IC50 = 23.14 nM

Shipping

Gel Pack

Storage

Store at -20°C

Preparing Stock Solutions

Molecular Structure

ConcentrationSolventMass	1 mg	5 mg	10 mg
1 mM	1.0261 ml	5.1303 ml	10.2605 ml
5 mM	0.2052 ml	1.0261 ml	2.0521 ml
10 mM	0.1026 ml	0.5130 ml	1.0261 ml
50 mM	0.0205 ml	0.1026 ml	0.2052 ml

Solubility
DMSO: 100 mg/mL (102.6 mM)

Product Description

ABT-263 is a novel inhibitor of antiapoptotic BCL-2 proteins and a new promising anticancer drug candidate.
ABT-263 is active against approximately one-half of the cell lines of the PPTP in vitro panel. The median IC50 for all of the lines in the panel is 1.91 µM. Navitoclax in combination with chemotherapy agents leads most ovarian cancer cell lines a synergistic response, and enhances the caspase activation in both SK-OV-3 and IGROV-1 cell lines.